Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin on Metacognitive Deficits in Schizophrenia
NCT04158167Completed
- Sponsor
- National Institute of Mental Health and Neurosciences
- Start
- Sep 2013
- Primary completion
- Dec 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of oxytocin in schizophrenia, sponsored by National Institute of Mental Health and Neurosciences. Primary endpoint: Functional brain connectivity changes at 90 minutes. Started Sep 2013; status: completed.
02
Drugs
oxytocin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04158167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158167.